Labguru in AstraZeneca deal

Labguru in AstraZeneca deal

Digital Science company BioData has licensed its Labguru system to AstraZeneca, the world's seventh largest pharmaceutical company.

Labguru is a web-based research and laboratory management system which offers a way to track projects and streamline collaboration between lab members and institutions, enabling scientists to share their research and collaborate across the globe. It is produced by BioData, one of the portfolio companies within Digital Science, Macmillan Science and Education's forward-looking technology business. 

AstraZeneca is to use Labguru for the global management of biological reagents used in pre-clinical research. 

The pharmaceutical company's vp of Reagents and Assay Development Lorenz Mayr said: "BioData's experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need."

BioData has offices in London, Boston and Tel Aviv. AstraZeneca operates in over 100 countries. 

Digital Science is not included in the merger currently underway between the majority of Macmillan Science and Education and Springer Business+Media, but will instead be wholly retained by Holtzbrinck.